View the Latest Edition of BioNetwork Here

BioNetwork West 2015 (past event)

October 26 - 28, 2015

View All Speakers

Nina Kjellson

General Partner
Canaan

Nina Kjellson joined Cannan’s healthcare team from InterWest Partners where she has been investing in healthcare start-ups since 2002. She focuses primarily on investments in biopharmaceuticals and digital health. Nina is co-founder and co-chair of ConsumerMed.org, a forum to address the convergence of health care and consumer innovation and serves as a mentor to Blueprint Health, a digital health incubator and Springboard Life Sciences, an accelerator for healthcare companies driven by women entrepreneurs. Investment themes include innovative therapeutics for serious and underserved conditions, IT-enabled transformation of healthcare delivery and patient/consumer engagement.

Current investments include Cidara (CDTX), Eiger Biopharmaceuticals, Lycera, Ocera (OCRX), Paratek (PRTK), and WellTok.

Previous investments include Labrys Biologics (acquired by Teva), Alt12 (acquired by Honest Company), Trius Therapeutics (TSRX; acquired by Cubist), CNS Therapeutics (acquired by Covidien), NovaCardia (acquired by Merck), and Aspreva (ASPV; acquired by Galenica)

Prior to InterWest, Nina was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a health care-focused hedge fund. Nina began her career conducting health policy and survey research with the Kaiser Family Foundation.

Nina received a B.A. in human biology from Stanford University (1997).

She serves on the California Leadership Council for the Nature Conservancy and has been nominated to join the board of the California Family Health Council.

Check out the incredible speaker line-up to see who will be joining Nina.

Download The Latest Agenda

Innovative Dealmaking

Friday, February 10th, 2017

14:05 PANEL: Understanding The Evolving Structure And Needs Of Big Pharma And Biotechs To Find The Perfect Partner

With patent cliffs, outcomes-based healthcare, M&A activity, and a growing global partnering environment, Big Pharma's partnering needs are constantly shifting. Organizations are responding to these shifts by restructing their BD groups, their focus, and their needs. Biotechs are also shifting their research, partnering processes, and resources to account for the changing environment. This panel will ensure you know how to most effectively go after your next partnership.
• Exploring current organizational structures of big pharma
• Who do biotechs, academia and other partners need to talk to and when?
• The differences between pharma and big biotechs when establishing partnerships
• How major corporate M&As can impact big pharma’s ability to partner
• Effective partnering tools for working with big pharma and biotechs